GenScript Biotech Corporation announced that reference is made to the announcements by it dated 21 September 2020, 22 November 2020, and 9 February 2021. Unless the context requires otherwise, terms used in this announcement shall have the same meanings as defined in the Announcements. The Board wishes to report on an update in connection with the Investigation pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). Each of Nanjing Jinsirui Biotechnology Co. Ltd. and Jiangsu Jinsirui Biotechnology Co. Ltd., three (3) employees and one (1) former employee who were involved in certain import and export activities of the Group, and Dr. Zhang Fangliang, being the former chairman and former chief executive officer of the Company and the former chairman of the board of directors and former chief executive officer of Legend Biotech, have been informed by the Zhenjiang Customs Anti-Smuggling Branch, the People's Republic of China (the "Authority") that the Investigation has been completed, and their respective matter has been handed over to the Zhenjiang Municipal People's Procuratorate (the "Procuratorate") for examination and prosecution. As advised by the PRC legal advisors of the Company, this is an expected and ordinary procedural development under the PRC legal system, and it would take time for the Procuratorate to make a decision on whether to file any formal charge on any entity or individual. As at the time of this announcement, to the best of the Company's knowledge, no formal charges have been made or filed against any entity or individual.